Neuromyelitis Optica Spectrum Disorder clinical trials

Explore recruiting neuromyelitis optica spectrum disorder clinical trials.

Recruiting neuromyelitis optica spectrum disorder studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neuromyelitis Optica Spectrum Disorder trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects with Neuromyelitis Optica Spectrum Disorder

Spain, Poland, Sweden, Netherlands, France

Therapeutic exploratory (Phase II) EU CTIS Study details

lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder (DEFEAT NMOSD)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)

France, Italy, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase III, Multicenter, Open-Label, Uncontrolled Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients with AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Italy, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neuromyelitis Optica Spectrum Disorder trials by city

Neuromyelitis Optica Spectrum Disorder in Toronto Neuromyelitis Optica Spectrum Disorder in Vancouver Neuromyelitis Optica Spectrum Disorder in Montreal Neuromyelitis Optica Spectrum Disorder in Calgary Neuromyelitis Optica Spectrum Disorder in Edmonton Neuromyelitis Optica Spectrum Disorder in Ottawa Neuromyelitis Optica Spectrum Disorder in Winnipeg Neuromyelitis Optica Spectrum Disorder in Quebec City Neuromyelitis Optica Spectrum Disorder in Hamilton Neuromyelitis Optica Spectrum Disorder in Kitchener Neuromyelitis Optica Spectrum Disorder in London Neuromyelitis Optica Spectrum Disorder in Halifax Neuromyelitis Optica Spectrum Disorder in New York Neuromyelitis Optica Spectrum Disorder in Los Angeles Neuromyelitis Optica Spectrum Disorder in Chicago Neuromyelitis Optica Spectrum Disorder in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease